Through many years of involvement and achievements in the pharmaceutical industry, Skyepharma’s development and manufacturing facility is eminently specialized in classic and complex Oral Solid Dosage Forms.
More than 20 years of experience in complex oral forms
Jacques Gonnella creates JAGO AG, a small Swiss private company specialized in development.
Ian Gowrie-Smith, founder of Medeva, creates SkyePharma plc as a virtual entity. Skyepharma then acquires JAGO AG, operating under that name before rebranding as Skyepharma AG two years later.
Skyepharma acquires its Saint Quentin Fallavier production site from Wyeth*. Skyepharma has subsequently invested in the site to adapt it to the production of modified-release tablets, particularly those using the patented Geomatrix® technology.
Skyepharma develops its business by acquiring several companies:
- The American company Depotech (San Diego), specialized in the development of sustained-release injectables, which became « Skyepharma Inc ».
- Bioglan Pharma (DK) and Hyal Pharmaceutical (Canada) Corporation, both specialized in topical products. Hyal originated Solaraze.
- The Montreal-based RTP pharma company that was the origin of Triglide.
* The Saint-Quentin-Fallavier plant was built in 1990 by the American laboratory Lederle, then a subsidiary of the American Cyanamid chemical group (Lederle then became Wyeth-Lederle, a subsidiary of the American Home Products group, which was itself acquired by Pfizer). The site replaced the former Oullins (Rhône) plant.